SE0101329D0 - Pharmaceutical formulation - Google Patents
Pharmaceutical formulationInfo
- Publication number
- SE0101329D0 SE0101329D0 SE0101329A SE0101329A SE0101329D0 SE 0101329 D0 SE0101329 D0 SE 0101329D0 SE 0101329 A SE0101329 A SE 0101329A SE 0101329 A SE0101329 A SE 0101329A SE 0101329 D0 SE0101329 D0 SE 0101329D0
- Authority
- SE
- Sweden
- Prior art keywords
- oxa
- butyl
- compositions
- diazabicyclo
- tert
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 2
- KZOCHEDMAHPYCK-UHFFFAOYSA-N 4-[3-[3-(3,3-dimethyl-2-oxobutyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonan-7-yl]propylamino]benzonitrile Chemical compound C1C(O2)CN(CC(=O)C(C)(C)C)CC2CN1CCCNC1=CC=C(C#N)C=C1 KZOCHEDMAHPYCK-UHFFFAOYSA-N 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- JRHUUZPSMQIWBQ-PELRDEGISA-N tert-butyl n-[2-[3-[(2s)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-7-yl]ethyl]carbamate Chemical compound C([C@@H](O)CN1CC2CN(CC(C1)O2)CCNC(=O)OC(C)(C)C)OC1=CC=C(C#N)C=C1 JRHUUZPSMQIWBQ-PELRDEGISA-N 0.000 abstract 1
- LAMDSCRMEIOKJI-UHFFFAOYSA-N tert-butyl n-[2-[7-[3-(4-cyanoanilino)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl]ethyl]carbamate Chemical compound C1C(O2)CN(CCNC(=O)OC(C)(C)C)CC2CN1CCCNC1=CC=C(C#N)C=C1 LAMDSCRMEIOKJI-UHFFFAOYSA-N 0.000 abstract 1
- ZEEVEFOISWRYMK-UHFFFAOYSA-N tert-butyl n-[2-[7-[4-(4-cyanophenyl)butyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl]ethyl]carbamate Chemical compound C1C(O2)CN(CCNC(=O)OC(C)(C)C)CC2CN1CCCCC1=CC=C(C#N)C=C1 ZEEVEFOISWRYMK-UHFFFAOYSA-N 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (26)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101329A SE0101329D0 (sv) | 2001-04-12 | 2001-04-12 | Pharmaceutical formulation |
| TW091106495A TWI257391B (en) | 2001-04-12 | 2002-04-01 | New pharmaceutical formulation suitable for antiarrhythmic compounds |
| ARP020101187A AR035806A1 (es) | 2001-04-12 | 2002-04-02 | Formulacion farmaceutica de liberacion inmediata apropiada para compuestos antiarritmicos, procedimiento para su preparacion, composicion farmaceutica solida, composicion liofilizada, uso de la formulacion o la composicion para la manufactura de un medicamento para ser usado en la profilaxis o trata |
| RU2003129230/15A RU2003129230A (ru) | 2001-04-12 | 2002-04-12 | 3,7-диазабицикло[3.3.1]-препараты как антиаритмические соединения |
| KR10-2003-7013299A KR20030088498A (ko) | 2001-04-12 | 2002-04-12 | 항부정맥 화합물로서의 3,7-디아자비시클로[3.3.1] 제제 |
| BR0208828-2A BR0208828A (pt) | 2001-04-12 | 2002-04-12 | Formulação farmacêutica de liberação imediata, processo para a preparação de uma formulação, composição farmacêutica sólida, processo para a formação de uma composição, uso de uma formulação, e, método de profilaxia ou tratamento de uma arritmia |
| CA002443473A CA2443473A1 (en) | 2001-04-12 | 2002-04-12 | 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds |
| DE60213084T DE60213084T2 (de) | 2001-04-12 | 2002-04-12 | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA |
| NZ528561A NZ528561A (en) | 2001-04-12 | 2002-04-12 | 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds |
| MXPA03009209A MXPA03009209A (es) | 2001-04-12 | 2002-04-12 | Formulaciones de 3,7-diazabiciclo-[3.3.1] como compuestos anti-arritmicos. |
| PL02366629A PL366629A1 (en) | 2001-04-12 | 2002-04-12 | 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds |
| EP02723011A EP1389212B1 (en) | 2001-04-12 | 2002-04-12 | 3,7-diazabicyclo 3.3.1| formulations as anti-arrythmic compounds |
| EEP200300495A EE200300495A (et) | 2001-04-12 | 2002-04-12 | 3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis |
| JP2002581444A JP2005500262A (ja) | 2001-04-12 | 2002-04-12 | 抗不整脈化合物としての３，７−ジアザビシクロ［３．３．１］製剤 |
| PCT/SE2002/000726 WO2002083689A1 (en) | 2001-04-12 | 2002-04-12 | 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds |
| HU0303486A HUP0303486A3 (en) | 2001-04-12 | 2002-04-12 | Compositions containing 3,7-diazabicyclo [3,3,1] compounds as anti-arrythmic compounds agents |
| US10/474,584 US20050037067A1 (en) | 2001-04-12 | 2002-04-12 | 3,7-Diazabicyclo [3.3.1]formulations as anti-arrhythmic compounds |
| IL15803302A IL158033A0 (en) | 2001-04-12 | 2002-04-12 | 3, 7-diazabicyclo [3.3.1] formulations as anti-arrhythmic compounds |
| CNA028116364A CN1514839A (zh) | 2001-04-12 | 2002-04-12 | 作为抗心律失常化合物的3,7-二氮杂双环[3.3.1]制剂 |
| AT02723011T ATE332902T1 (de) | 2001-04-12 | 2002-04-12 | 3,7-diazabicycloc3.3.1)-formulierungen als antiarrhythmika |
| SK1256-2003A SK12562003A3 (sk) | 2001-04-12 | 2002-04-12 | Formulácie obsahujúce deriváty 3,7-diazabicyklo-[3.3.1]-zlúčenín, spôsob ich prípravy a ich použitie ako antiarytmických činidiel |
| CZ20032774A CZ20032774A3 (cs) | 2001-04-12 | 2002-04-12 | Kompozice obsahující deriváty 3,7-diazabicyklo[3.3.1]sloučenin, způsob jejich přípravy a jejich použití jako antiarytmických činidel |
| ZA200307756A ZA200307756B (en) | 2001-04-12 | 2003-10-03 | 3,7-Diazabicyclo[3.3.1]formulations as anti-arrythmic compounds. |
| BG108234A BG108234A (bg) | 2001-04-12 | 2003-10-06 | 3,7-диазабицикло[ 3.3.1] състави включващи антиаритмични съединения |
| NO20034529A NO20034529L (no) | 2001-04-12 | 2003-10-09 | 3,7-diazabicyklo(3,3,1) - formuleringer som anti-arytmi- forbindelser |
| IS6989A IS6989A (is) | 2001-04-12 | 2003-10-10 | 3,7-díasabísýkló [3.3.1] blöndur sem efnasambönd gegn sláttarglöpum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101329A SE0101329D0 (sv) | 2001-04-12 | 2001-04-12 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0101329D0 true SE0101329D0 (sv) | 2001-04-12 |
Family
ID=20283785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0101329A SE0101329D0 (sv) | 2001-04-12 | 2001-04-12 | Pharmaceutical formulation |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20050037067A1 (no) |
| EP (1) | EP1389212B1 (no) |
| JP (1) | JP2005500262A (no) |
| KR (1) | KR20030088498A (no) |
| CN (1) | CN1514839A (no) |
| AR (1) | AR035806A1 (no) |
| AT (1) | ATE332902T1 (no) |
| BG (1) | BG108234A (no) |
| BR (1) | BR0208828A (no) |
| CA (1) | CA2443473A1 (no) |
| CZ (1) | CZ20032774A3 (no) |
| DE (1) | DE60213084T2 (no) |
| EE (1) | EE200300495A (no) |
| HU (1) | HUP0303486A3 (no) |
| IL (1) | IL158033A0 (no) |
| IS (1) | IS6989A (no) |
| MX (1) | MXPA03009209A (no) |
| NO (1) | NO20034529L (no) |
| NZ (1) | NZ528561A (no) |
| PL (1) | PL366629A1 (no) |
| RU (1) | RU2003129230A (no) |
| SE (1) | SE0101329D0 (no) |
| SK (1) | SK12562003A3 (no) |
| TW (1) | TWI257391B (no) |
| WO (1) | WO2002083689A1 (no) |
| ZA (1) | ZA200307756B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI259836B (en) * | 2001-04-12 | 2006-08-11 | Astrazeneca Ab | Modified release formulation suitable for antiarrhythmic compounds |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| GB0523810D0 (en) * | 2005-11-23 | 2006-01-04 | Astrazeneca Ab | Pharmaceutical compositions |
| JP5235676B2 (ja) * | 2005-12-20 | 2013-07-10 | レツク・フアーマシユーテイカルズ・デー・デー | （ｅ）−７−〔４−（４−フルオロフェニル）−６−イソプロピル−２−〔メチル（メチルスルホニル）アミノ〕ピリミジン−５−イル〕−（３ｒ，５ｓ）−３，５−ジヒドロキシヘプタ−６−エン酸を含む医薬組成物 |
| US20080085303A1 (en) * | 2006-10-10 | 2008-04-10 | Penwest Pharmaceuticals Co. | Robust sustained release formulations of oxymorphone and methods of use thereof |
| CA2644179C (en) * | 2007-11-21 | 2018-09-25 | Pharmascience Inc. | Novel pharmaceutical composition comprising a disintegration matrix |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| US9408835B2 (en) * | 2013-03-29 | 2016-08-09 | Astellas Pharma Inc. | Pharmaceutical composition for oral administration |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3732094A1 (de) * | 1987-09-24 | 1989-04-06 | Basf Ag | Bispidinderivate als klasse iii-antiarrhythmika |
| US5110933A (en) * | 1989-11-13 | 1992-05-05 | Board Of Regents Of Oklahoma State University | Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof |
| DE4402933A1 (de) * | 1994-02-01 | 1995-08-03 | Kali Chemie Pharma Gmbh | Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel |
| SE9704709D0 (sv) * | 1997-12-17 | 1997-12-17 | Astra Ab | Pharmaceutically active compounds |
| HUP0202214A3 (en) * | 1999-04-09 | 2002-12-28 | Astrazeneca Ab | Adamantane derivatives, preparation and use thereof |
| SE9903759D0 (sv) * | 1999-10-18 | 1999-10-18 | Astra Ab | Pharmaceutically active compounds |
| US6500457B1 (en) * | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
-
2001
- 2001-04-12 SE SE0101329A patent/SE0101329D0/xx unknown
-
2002
- 2002-04-01 TW TW091106495A patent/TWI257391B/zh not_active IP Right Cessation
- 2002-04-02 AR ARP020101187A patent/AR035806A1/es not_active Application Discontinuation
- 2002-04-12 SK SK1256-2003A patent/SK12562003A3/sk unknown
- 2002-04-12 EP EP02723011A patent/EP1389212B1/en not_active Expired - Lifetime
- 2002-04-12 RU RU2003129230/15A patent/RU2003129230A/ru not_active Application Discontinuation
- 2002-04-12 MX MXPA03009209A patent/MXPA03009209A/es not_active Application Discontinuation
- 2002-04-12 IL IL15803302A patent/IL158033A0/xx unknown
- 2002-04-12 NZ NZ528561A patent/NZ528561A/en unknown
- 2002-04-12 BR BR0208828-2A patent/BR0208828A/pt not_active IP Right Cessation
- 2002-04-12 AT AT02723011T patent/ATE332902T1/de not_active IP Right Cessation
- 2002-04-12 HU HU0303486A patent/HUP0303486A3/hu unknown
- 2002-04-12 CA CA002443473A patent/CA2443473A1/en not_active Abandoned
- 2002-04-12 WO PCT/SE2002/000726 patent/WO2002083689A1/en not_active Ceased
- 2002-04-12 JP JP2002581444A patent/JP2005500262A/ja not_active Withdrawn
- 2002-04-12 PL PL02366629A patent/PL366629A1/xx not_active Application Discontinuation
- 2002-04-12 CN CNA028116364A patent/CN1514839A/zh active Pending
- 2002-04-12 EE EEP200300495A patent/EE200300495A/xx unknown
- 2002-04-12 CZ CZ20032774A patent/CZ20032774A3/cs unknown
- 2002-04-12 US US10/474,584 patent/US20050037067A1/en not_active Abandoned
- 2002-04-12 DE DE60213084T patent/DE60213084T2/de not_active Expired - Fee Related
- 2002-04-12 KR KR10-2003-7013299A patent/KR20030088498A/ko not_active Withdrawn
-
2003
- 2003-10-03 ZA ZA200307756A patent/ZA200307756B/en unknown
- 2003-10-06 BG BG108234A patent/BG108234A/bg unknown
- 2003-10-09 NO NO20034529A patent/NO20034529L/no not_active Application Discontinuation
- 2003-10-10 IS IS6989A patent/IS6989A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200307756B (en) | 2005-01-03 |
| BR0208828A (pt) | 2004-03-09 |
| MXPA03009209A (es) | 2004-01-29 |
| US20050037067A1 (en) | 2005-02-17 |
| WO2002083689A1 (en) | 2002-10-24 |
| DE60213084D1 (de) | 2006-08-24 |
| IS6989A (is) | 2003-10-10 |
| CN1514839A (zh) | 2004-07-21 |
| PL366629A1 (en) | 2005-02-07 |
| SK12562003A3 (sk) | 2004-03-02 |
| CA2443473A1 (en) | 2002-10-24 |
| RU2003129230A (ru) | 2005-04-10 |
| DE60213084T2 (de) | 2007-01-11 |
| KR20030088498A (ko) | 2003-11-19 |
| NZ528561A (en) | 2005-03-24 |
| HUP0303486A2 (hu) | 2004-01-28 |
| NO20034529L (no) | 2003-12-08 |
| TWI257391B (en) | 2006-07-01 |
| EE200300495A (et) | 2003-12-15 |
| AR035806A1 (es) | 2004-07-14 |
| EP1389212B1 (en) | 2006-07-12 |
| ATE332902T1 (de) | 2006-08-15 |
| BG108234A (bg) | 2005-04-30 |
| EP1389212A1 (en) | 2004-02-18 |
| CZ20032774A3 (cs) | 2004-01-14 |
| JP2005500262A (ja) | 2005-01-06 |
| IL158033A0 (en) | 2004-03-28 |
| HUP0303486A3 (en) | 2005-04-28 |
| NO20034529D0 (no) | 2003-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0208829A (pt) | Sal farmaceuticamente aceitável, composto, processos para a preparação de um sal, de um composto e de uma forma cristalina dos compostos, formulação farmacêutica, uso de um composto, e, método de profilaxia ou tratamento de uma arritmia | |
| ATE104971T1 (de) | 2-aminopyrimidinon-derivate. | |
| CO5550466A2 (es) | Formulacion farmaceutica | |
| BR0317294A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários | |
| DE60230270D1 (de) | 5-halo-tryptaminderivate als 5-ht6 und/oder 5-ht7 rezeptorliganden | |
| ZA200408283B (en) | 7-aryl-3,9-diazabicyclo (3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardivascular or rental diseases | |
| DE69131759D1 (de) | An den Positionen 2 und 9 substituierte 4H-pyrido-(1,2-a)pyrimidin-4-one | |
| AR026064A1 (es) | Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios. | |
| JP2025503996A5 (no) | ||
| NO172645C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-aminopyrimidinonderivater | |
| BR0208828A (pt) | Formulação farmacêutica de liberação imediata, processo para a preparação de uma formulação, composição farmacêutica sólida, processo para a formação de uma composição, uso de uma formulação, e, método de profilaxia ou tratamento de uma arritmia | |
| DK1307445T3 (da) | Benzofuranderivater og deres anvendelse som antibakterielle midler | |
| BR0114366A (pt) | Composto, formulação farmacêutica, uso de um composto, método de profilaxia ou tratamento de uma arritimia e processo para a preparação de um composto | |
| MY141595A (en) | New modified release formulation suitable for antiarrhythmic compounds | |
| SE0002729D0 (sv) | Novel compound form | |
| WO2004089943A8 (en) | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | |
| CA2438813A1 (en) | Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as ip antagonists | |
| EP1747200B8 (en) | Alkaloid compounds and their use as anti-malarial drugs | |
| EA200400864A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ 2-(4-ЭТОКСИФЕНИЛ)-3-(4-МЕТАНСУЛЬФОНИЛФЕНИЛ)ПИРАЗОЛО[1,5-b]ПИРИДАЗИН В ФОРМЕ НАНОЧАСТИЦ |